NAFLD increases the risk of early atherosclerotic lesions

A study presented today at the International Liver Congress 2013 – which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) – showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

NAFLD is one of the most common causes of . Patients with NAFLD have an excess prevalence of CV events and typically have an increase frequency of already known to be directly related to atherosclerosis. As a consequence, it remains unclear if the presence of fatty liver should be regarded as an for CV disease.

Over 5000 patients with two or more traditional CV risk factors (without previous CV events), low (<50g/day) and without known liver diseases (viral hepatitis, hemochromatosis, Wilson disease or drug induced liver injury) underwent carotid ultrasonography with measurement of carotid intima-media thickness (C-IMT). Carotid plaques (CP) were defined as C-IMT>1,5 mm at carotid bifurcation. The Fatty Liver Index (FLI), a surrogate marker of hepatic steatosis when >60, and the Framingham score (FRS) were calculated.

Patients with a FLI of 60 or more also had a higher BMI and increased levels of (ALT, AST, GGT) (p<0.0001). They also had higher C-IMT and higher FRS (0.64+0.16 vs. 0.61+0.13, p< 0,0001 and 14.7+8.8 vs. 8.3+6.6, p< 0.0001 respectively). In multivariate analysis FLI was independently associated with C-IMT (p< 0.0001) and CP (beta =0.179, p=0.01), independent of age, cholesterol level, presence of diabetes or high blood pressure.

This study demonstrated that NAFLD is highly prevalent in patients at high risk of CV diseases and is an independent predictor of early atherosclerosis and 10-years CV risk beyond classical CV risk factors. These findings strengthen the evidence that NAFLD is a heterogeneous entity requiring a multidisciplinary approach and modified screening strategies.

Type-2 diabetes and dyslipidemia are known risk factors usually associated with cardiovascular and liver-related deaths in NAFLD. A second study presented today evaluated the 10-year prognostic value of non-invasive markers and SteatoTest for overall survival (OS), survival without liver-related death (LRD) and cardiovascular-related death (CVD) in patients with diabetes and/or dyslipidemia without known liver disease.

Over 2000 patients were prospectively followed for 12 years and collected. The study found in diabetics, regardless of associated hyperlipidaemia, FibroTest had a significant 10-year prognostic value for the overall and without liver-related death survivals. SteatoTest was also predictive of CV-related death in hyperlipidemia patients.

Both OS and survival without CVD were significantly higher in the hyperlipidemia group than in the diabetic or diabetic with hyperlipidemia group. The hyperlipidemia group with advanced steatosis (AS) tested by Steatotest had lower survival without-CVD, compared to non-AS: 97(94-99) vs. 99(98-99, P=0.004). FibroTest remained significant for the prediction of OS in the diabetic group [risk ratio (RR) = 136.9 (95%CI 11.6-1610; P< 0.0001)] and in the diabetic with hyperlipidemia group [RR=7.1 (95%CI 2.1-24; P< 0.0001)].

The study concluded that patients with type-2 diabetes, especially those with associated hyperlipidemia, presented particularly higher rates of advanced fibrosis and steatosis as well as higher overall and liver-related mortalities than those with isolated hyperlipidemia.

EASL's Education Councillor, Jean-Francois Dufour commented. "These studies reinforce the view that in patients with other risk factors such as diabetes or other metabolic impairment, the degree of liver fat deposition is an important determinant of long term mortality, not only due to liver disease progression, but other causes, particularly cardiovascular events. Although patients with NAFLD have long been known to suffer from excess cardiovascular disease, it was uncertain if this was mediated through a higher risk of earlier . These studies show that NAFLD is an of cardiovascular risk."

More information: References:

1 Pais R et al, NAFLD IS SIGNIFICANTLY INCREASED IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS AND IS CORRELATED WITH EARLY PREDICTORS OF ATHEROSCLEROSIS AND THE FRAMINGHAM SCORE. Presented at the International Liver Congress 2013

2 Perazzo H et al, 10-YEARS PROGNOSTIC VALUE OF FIBROTEST AND STEATOTEST FOR LIVER-RELATED AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE-2 DIABETES AND/OR HYPERLIPIDEMIA. Presented at the International Liver Congress 2013

Provided by European Association for the Study of the Liver

not rated yet
add to favorites email to friend print save as pdf

Related Stories

NAFLD independently linked to cardiovascular disease

Jun 07, 2012

(HealthDay) -- Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk of cardiovascular disease (CVD), but it is not associated with a statistically significantly increased ...

Recommended for you

Restrictions lifted at British bird flu farm

15 hours ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

Dec 20, 2014

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.